Binge Eating Disorder: Opportunity Analysis and Forecasts to 2027
- Pages: 107
- Published: June 2018
- Report Code: GDHC086POA
Binge eating disorder (BED) was first noted by Albert Stunkard in 1959, who described the consuming of large quantities of food at irregular intervals and its link to obesity. However, BED was only officially recognized as a distinct eating disorder in 2013, with the publication of the Diagnosis and Statistical Manual, Fifth Edition. Previously, the American Psychiatry Association (APA) had listed binge eating as a feature of eating disorders not otherwise specified. Since its recognition as a distinct clinical disorder, awareness of BED has been slowly increasing, but BED is currently only properly diagnosed in a small proportion of cases.
BED is currently the most common eating disorder in the US. It tends to appear during late adolescence or adulthood, which is later than anorexia nervosa (AN) and bulimia nervosa (BN) typically present. Cognitive behavioural therapy (CBT) is regarded as the first-line treatment for BED, but pharmacotherapy is also available as an adjunctive or alternative treatment to CBT. BED is associated with a number of comorbidities, including depression, anxiety, and substance abuse, which must be taken into account when selecting pharmacotherapy. Similarly to other eating disorders, individuals with BED can take decades to recover without treatment, and of those who do receive treatment, some may recover in less than a year, but it more commonly takes 37 years. At present only one pharmacotherapy is approved in the 7MM for the treatment of BED, Shire’s Vyvanse (lisdexamfetamine dimesylate), which received an approved label expansion to include BED by the FDA in 2015. However, other therapeutics including antidepressants, anticonvulsants, and obesity drugs, are commonly used as off-label treatments.
Key Questions Answered
How will the BED therapeutic market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2017–2027?
What products are in clinical development for BED?
How do the clinical and commercial attributes of drugs in development for BED compare with one another, and against existing treatment options?
What are the remaining unmet needs in BED treatment management?
What drivers and barriers will affect BED therapeutics sales in the 7MM over the forecast period?
Overview of BED, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
Topline BED market revenue from 2017–2027. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting BED therapeutics sales in the 7MM.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development and detailed analysis of pipeline products.
Analysis of the current and future market competition in the global BED therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global BED therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BED therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Binge Eating Disorder (BED): Executive Summary
2.1 Rapid Growth Expected in the BED Marketplace from 2017–2027
2.2 Targeting Comorbidities Is a Dependable BED Treatment Development Route
2.3 Lack of Awareness Is the Greatest Unmet Need in BED Care
2.4 Dasotraline Expected to Become a Leading Pharmacotherapy for BED by 2027
2.5 What Do Physicians Think?
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for BED (2017–2027)
5.5.1 12-Month Diagnosed Prevalent Cases of BED
5.5.2 Age-Specific 12-Month Diagnosed Prevalent Cases of BED
5.5.3 Sex-Specific 12-Month Diagnosed Prevalent Cases of BED
5.5.4 12-Month Diagnosed Prevalent Cases of BED by BMI
5.5.5 12-Month Diagnosed Prevalent Cases of BED by BMI and Comorbid Mood Disorder
5.5.6 12-Month Diagnosed Prevalent Cases of BED with Substance Abuse Disorder
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
7.2 Improved Awareness and Diagnosis of BED
7.3 Larger Pool of Approved BED Pharmacotherapies
7.4 Clinical Evidence for Long-Term Pharmacotherapy Efficacy
7.5 Increased Access to Psychotherapy
8 R&D Strategies
8.1.1 Targeting the Brain’s Reward System Receptors
8.1.2 Targeting Key Comorbidities of BED
8.1.3 Repurposing Weight-Loss Therapies
8.2 Clinical Trial Design
8.2.1 Binge Eating or Psychological Endpoints
8.2.2 Psychotherapy Inclusive
8.2.3 Clinical Trial Duration
9 Pipeline Assessment
9.2 Clinical Development of Off-Label BED Products
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
11.3.1 Forecasting Methodology
11.3.2 Diagnosed Patients
11.3.3 Percent Drug-Treated Patients
11.3.4 Drugs Included in Each Therapeutic Class
11.3.5 Launch and Patent Expiry Dates
11.3.6 General Pricing Assumptions
11.3.7 Individual Drug Assumptions
11.3.8 Generic Erosion
11.3.9 Pricing of Pipeline Agents
11.3.10 Influence of Clinical Evidence on Off-Label Use in BED
11.4 Primary Research – KOLs Interviewed for This Report
11.5 Primary Research – Prescriber Survey
11.6 About the Authors
11.6.2 Therapy Area Directors
11.6.4 Managing Epidemiologist
11.6.5 Global Director of Therapy Analysis and Epidemiology
11.6.6 Global Head and EVP of Healthcare Operations and Strategy
11.7 About GlobalData
11.8 Contact Us
List of Tables
Table 1: BED: Key Metrics in the 7MM
Table 2: BED Severity Grading as Defined by DSM-5
Table 3: Risk Factors and Comorbidities for BED
Table 4: Treatment Guidelines for BED
Table 5: Leading Treatments for BED, 2017
Table 6: Comparison of Therapeutic Classes in Development for BED, 2017–2027
Table 7: Approved Drugs in Development for BED, 2018
Table 8: Clinical Benchmark of Key Pipeline Drugs – BED
Table 9: Commercial Benchmark of Key Pipeline Drugs – BED
Table 10: Key Events Impacting Sales for BED, 2017–2027
Table 11: Global Drivers and Barriers in the BED Market, 2017–2027
Table 12: Key Historical and Projected Launch Dates (BED Approval Date in Parentheses)
Table 13: Key Historical and Projected Patent Expiry Dates for BED
Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for BED in 2017 and 2027
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Vyvanse
Figure 3: Anatomy of the Reward System in the Human Brain
Figure 4: Age-Standardized 12-Month Diagnosed Prevalence of BED in the 7MM, Ages ≥13 Years, 2017
Figure 5: Sources Used and Not Used for Diagnosed Prevalent Cases of BED
Figure 6: Sources Used and Not Used for Diagnosed Prevalent Cases of BED by BMI
Figure 7: Sources Used for Diagnosed Prevalent Cases of BED by BMI and Comorbid Mood Disorder
Figure 8: Sources Used for Diagnosed Prevalent Cases of BED with Substance Abuse Disorder
Figure 9: 12-Month Diagnosed Prevalent Cases of BED, 7MM, Men and Women, Ages ≥13 Years, N, 2017
Figure 10: Age-Specific 12-Month Diagnosed Prevalent Cases of BED, 7MM, Men and Women, Ages ≥13 Years, N, 2017
Figure 11: Sex-Specific 12-Month Diagnosed Prevalent Cases of BED, 7MM, Ages ≥13 Years, N, 2017
Figure 12: 12-Month Diagnosed Prevalent Cases of BED by BMI, 7MM, Men and Women, Ages ≥13 Years, N, 2017
Figure 13: 12-Month Diagnosed Prevalent Cases of BED by BMI and Comorbid Mood Disorder, 7MM, Men and Women, Ages ≥13 Years, N, 2017
Figure 14: 12-Month Diagnosed Prevalent Cases of BED with Substance Abuse Disorder, 7MM, Men and Women, Ages ≥13 Years, N, 2017
Figure 15: Breakdown of the Main Psychotherapy Techniques Applied to BED
Figure 16: Unmet Needs and Opportunities in BED
Figure 17: Overview of the Clinical Development in BED
Figure 18: Key Ongoing Clinical Trials for BED Therapeutics in the 7MM
Figure 19: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Vyvanse
Figure 20: Global (7MM) Sales Forecast by Country for BED in 2017 and 2027
Figure 21: Global Sales Forecast by Class for BED in 2017 and 2027
Figure 22: Sales Forecast by Class for BED in the US in 2017 and 2027
Figure 23: Sales Forecast by Class for BED in the 5EU in 2017 and 2027
Figure 24: Sales Forecast by Class for BED in Japan in 2017 and 2027